Literature DB >> 19608977

Structure and function of HDL mimetics.

Mohamad Navab1, Ishaiahu Shechter, G M Anantharamaiah, Srinivasa T Reddy, Brian J Van Lenten, Alan M Fogelman.   

Abstract

HDL mimetics have been constructed from a number of peptides and proteins with varying structures, all of which bind lipids found in HDL. HDL mimetics containing a peptide or protein have been constructed with as few as 4 and as many as 243 amino acid residues. Some HDL mimetics have been constructed with lipid but without a peptide or protein component. Some HDL mimetics promote cholesterol efflux, some have been shown to have a remarkable ability to bind oxidized lipids compared to human apolipoprotein A-I (apoA-I). Many of these peptides have been shown to have antiinflammatory properties. Based on studies in a number of animal models and in early human clinical trials, HDL mimetics appear to have promise as diagnostic and therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608977      PMCID: PMC2860541          DOI: 10.1161/ATVBAHA.109.187518

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  54 in total

1.  The HDL proteome: a marker--and perhaps mediator--of coronary artery disease.

Authors:  Jay W Heinecke
Journal:  J Lipid Res       Date:  2008-12-05       Impact factor: 5.922

2.  Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.

Authors:  Amar A Sethi; John A Stonik; Fairwell Thomas; Steve J Demosky; Marcelo Amar; Edward Neufeld; H Bryan Brewer; W Sean Davidson; Wilissa D'Souza; Dmitri Sviridov; Alan T Remaley
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

Review 3.  Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.

Authors:  Brian J Van Lenten; Mohamad Navab; G M Anantharamaiah; Georgette M Buga; Srinivasa T Reddy; Alan M Fogelman
Journal:  Curr Opin Investig Drugs       Date:  2008-11

4.  Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

Authors:  Sanjay Patel; Brian G Drew; Shirley Nakhla; Stephen J Duffy; Andrew J Murphy; Phillip J Barter; Kerry-Anne Rye; Jaye Chin-Dusting; Anh Hoang; Dmitri Sviridov; David S Celermajer; Bronwyn A Kingwell
Journal:  J Am Coll Cardiol       Date:  2009-03-17       Impact factor: 24.094

5.  A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.

Authors:  Mohamad Navab; Piotr Ruchala; Alan J Waring; Robert I Lehrer; Susan Hama; Greg Hough; Mayakonda N Palgunachari; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2009-02-18       Impact factor: 5.922

6.  High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus.

Authors:  Brian G Drew; Stephen J Duffy; Melissa F Formosa; Alaina K Natoli; Darren C Henstridge; Sally A Penfold; Walter G Thomas; Nigora Mukhamedova; Barbora de Courten; Josephine M Forbes; Felicia Y Yap; David M Kaye; Gerrit van Hall; Mark A Febbraio; Bruce E Kemp; Dmitri Sviridov; Gregory R Steinberg; Bronwyn A Kingwell
Journal:  Circulation       Date:  2009-04-06       Impact factor: 29.690

7.  Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease.

Authors:  Shaila P Handattu; David W Garber; Candyce E Monroe; Thomas van Groen; Inga Kadish; Gaurav Nayyar; Dongfeng Cao; Mayakonda N Palgunachari; Ling Li; G M Anantharamaiah
Journal:  Neurobiol Dis       Date:  2009-04-01       Impact factor: 5.996

8.  The effect of large unilamellar vesicles on vascular function in patients with coronary atherosclerosis.

Authors:  Todd Anderson; Francois Charbonneau; Sammy Chan; Eva Lonn
Journal:  Atherosclerosis       Date:  2008-02-08       Impact factor: 5.162

Review 9.  Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis.

Authors:  Matthias Briel; Ignacio Ferreira-Gonzalez; John J You; Paul J Karanicolas; Elie A Akl; Ping Wu; Boris Blechacz; Dirk Bassler; Xinge Wei; Asheer Sharman; Irene Whitt; Suzana Alves da Silva; Zahira Khalid; Alain J Nordmann; Qi Zhou; Stephen D Walter; Noah Vale; Neera Bhatnagar; Christopher O'Regan; Edward J Mills; Heiner C Bucher; Victor M Montori; Gordon H Guyatt
Journal:  BMJ       Date:  2009-02-16

10.  The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice.

Authors:  Stephen J Peterson; Dong Hyun Kim; Ming Li; Vincenzo Positano; Luca Vanella; Luigi F Rodella; Francesco Piccolomini; Nitin Puri; Amalia Gastaldelli; Claudia Kusmic; Antonio L'Abbate; Nader G Abraham
Journal:  J Lipid Res       Date:  2009-02-17       Impact factor: 5.922

View more
  49 in total

1.  A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.

Authors:  Marcelo J A Amar; Toshihiro Sakurai; Akiko Sakurai-Ikuta; Denis Sviridov; Lita Freeman; Lusana Ahsan; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2014-11-13       Impact factor: 4.030

2.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

Review 3.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

4.  Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.

Authors:  Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Shaila P Handattu; Vinod K Mishra; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-06-23       Impact factor: 5.162

5.  L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice.

Authors:  Satoshi Imaizumi; Victor Grijalva; Mohamad Navab; Brian J Van Lenten; Alan C Wagner; G M Anantharamiah; Alan M Fogelman; Srinivasa T Reddy
Journal:  Drug Metab Lett       Date:  2010-08

Review 6.  Atherosclerosis: current pathogenesis and therapeutic options.

Authors:  Christian Weber; Heidi Noels
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

7.  L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.

Authors:  Feng Gao; Sergio X Vasquez; Feng Su; Svetlana Roberts; Neha Shah; Victor Grijalva; Satoshi Imaizumi; Arnab Chattopadhyay; Ekambaram Ganapathy; David Meriwether; Brad Johnston; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Integr Biol (Camb)       Date:  2011-02-01       Impact factor: 2.192

8.  4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.

Authors:  Geoffrey D Wool; Veneracion G Cabana; John Lukens; Peter X Shaw; Christoph J Binder; Joseph L Witztum; Catherine A Reardon; Godfrey S Getz
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

9.  The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.

Authors:  C Roger White; Geeta Datta; Landon Wilson; Mayakonda N Palgunachari; G M Anantharamaiah
Journal:  Chem Phys Lipids       Date:  2019-01-29       Impact factor: 3.329

10.  L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation.

Authors:  Georgette M Buga; Mohamad Navab; Satoshi Imaizumi; Srinivasa T Reddy; Babak Yekta; Greg Hough; Shawn Chanslor; G M Anantharamaiah; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.